Skip to main content

#Coronavirus Disease Research #References (by AMEDEO, February 1 '25)

Image
By G.M.

 


    Antiviral Res

  1. WU Q, Wu H, Hu Y, Zheng X, et al
    Immune evasion of Omicron variants JN.1, KP.2, and KP.3 to the polyclonal and monoclonal antibodies from COVID-19 convalescents and vaccine recipients.
    Antiviral Res. 2025 Jan 24:106092. doi: 10.1016/j.antiviral.2025.106092.
    PubMed         Abstract available


    Infect Control Hosp Epidemiol

  2. HANKINS RJ, Handke L, Fey PD, Cavalieri RJ, et al
    Prospective, crossover, comparative study of two methods of chlorhexidine bathing.
    Infect Control Hosp Epidemiol. 2025 Jan 30:1-6. doi: 10.1017/ice.2024.
    PubMed         Abstract available

  3. PISCHEL L, Aguolu OG, Ahmed N, Campbell MM, et al
    Social mixing patterns of United States healthcare personnel at a quaternary health center: a prospective observational study.
    Infect Control Hosp Epidemiol. 2025 Jan 30:1-9. doi: 10.1017/ice.2024.
    PubMed         Abstract available


    J Infect

  4. ZSIGMOND B, Trecchi N, Ladhani SN, Doerholt K, et al
    Early outpatient treatment of SARS-COV-2 infection in non-hospitalised high-risk paediatric patients in London, UK.
    J Infect. 2025;90:106425.
    PubMed        

  5. BENNETT C, Chau G, Clayton E, Chu L, et al
    Safety and Immunogenicity of Omicron Protein Vaccines in mRNA-Vaccinated Adolescents: A Phase 3, Randomised Trial.
    J Infect. 2025 Jan 26:106428. doi: 10.1016/j.jinf.2025.106428.
    PubMed         Abstract available


    J Med Virol

  6. LI J, Yan H, Li J, Ling F, et al
    Low Neutralization of SARS-CoV-2 Omicron BA5248, XBB15 and JN1 by Homologous Booster and Breakthrough Infection.
    J Med Virol. 2025;97:e70189.
    PubMed         Abstract available


  7. Correction to "Serum-Derived Bovine Immunoglobulin Treatment in COVID-19 Is Associated With Faster Resolution of Symptoms: A Randomized Pilot Clinical Trial".
    J Med Virol. 2025;97:e70202.
    PubMed        


    J Virol

  8. WANG Y, Xia B, Gao Z
    A comprehensive review of current insights into the virulence factors of SARS-CoV-2.
    J Virol. 2025 Jan 29:e0204924. doi: 10.1128/jvi.02049.
    PubMed         Abstract available

  9. LIU C, Kong N, Liu H, Zhang Y, et al
    FSTL1 and TLR4 interact with PEDV structural proteins to promote virus adsorption to host cells.
    J Virol. 2025;99:e0183724.
    PubMed         Abstract available

  10. LYTRAS S, Lamb KD, Ito J, Grove J, et al
    Pathogen genomic surveillance and the AI revolution.
    J Virol. 2025 Jan 29:e0160124. doi: 10.1128/jvi.01601.
    PubMed         Abstract available

  11. DUGUAY BA, Tooley TH, Pringle ES, Rohde JR, et al
    A yeast-based reverse genetics system to generate HCoV-OC43 reporter viruses encoding an eighth subgenomic RNA.
    J Virol. 2025 Jan 30:e0167124. doi: 10.1128/jvi.01671.
    PubMed         Abstract available

  12. SAMAAN P, Korosec CS, Budylowski P, Chau SLL, et al
    mRNA vaccine-induced SARS-CoV-2 spike-specific IFN-gamma and IL-2 T-cell responses are predictive of serological neutralization and are transiently enhanced by pre-existing cross-reactive immunity.
    J Virol. 2025 Jan 31:e0168524. doi: 10.1128/jvi.01685.
    PubMed         Abstract available


    JAMA

  13. ANDERER S
    COVID-19 Tied to Long-Term Kidney Function Decline.
    JAMA. 2025 Jan 24. doi: 10.1001/jama.2024.28058.
    PubMed        


    Lancet

  14. MUMFORD L, Hogg R, Taylor A, Lanyon P, et al
    Impact of SARS-CoV-2 spike antibody positivity on infection and hospitalisation rates in immunosuppressed populations during the omicron period: the MELODY study.
    Lancet. 2025;405:314-328.
    PubMed         Abstract available

  15. KERR S, Robertson C, Sheikh A
    Undervaccination and severe COVID-19 outcomes - Authors' reply.
    Lancet. 2025;405:302.
    PubMed        

  16. MORRIS JA
    Undervaccination and severe COVID-19 outcomes.
    Lancet. 2025;405:301-302.
    PubMed        

  17. JOFFE AR
    Undervaccination and severe COVID-19 outcomes.
    Lancet. 2025;405:301.
    PubMed        

  18. DUNCAN CJA
    Antibody testing to predict SARS-CoV-2 risk in immunocompromised people.
    Lancet. 2025;405:276-278.
    PubMed        


    Nature

  19. RAHARINIRINA NA, Gubela N, Bornigen D, Smith MR, et al
    SARS-CoV-2 evolution on a dynamic immune landscape.
    Nature. 2025 Jan 29. doi: 10.1038/s41586-024-08477.
    PubMed         Abstract available

  20. MORALES AE, Dong Y, Brown T, Baid K, et al
    Bat genomes illuminate adaptations to viral tolerance and disease resistance.
    Nature. 2025 Jan 29. doi: 10.1038/s41586-024-08471.
    PubMed         Abstract available
Labels:

Comments

Post a Comment

Popular posts from this blog

#Neuroinvasive #Oropouche virus in a patient with #HIV from extra-Amazonian #Brazil

By G.M.
{Excerpt} A novel reassortant Oropouche virus (OROV) lineage (with medium [M], large [L], and small [S] RNA segments : M1L2S2) has driven Brazil's largest and most geographically widespread OROV epidemic , expanding beyond the endemic Amazon basin to establish local transmission across multiple Brazilian states and other previously unaffected Latin American countries . The rapid spread of this lineage underscores its evolutionary potential and reinforces its significance as a public health threat .1 Similar to chikungunya and Zika viruses, expanding arboviruses can exhibit unexpected clinical and epidemiological shifts , including vertical transmissions , neuroinvasive effects, and potentially fatal outcomes.2–4 Although OROV typically causes self-limited febrile illness, accumulating clinical and experimental evidence suggests neurotropic potential .5 This Correspondence describes the first confirmed case of neuroinvasive OROV infection caused by the emergent M1L2S2 lineage in ext...
Post a Comment
Read more »

No evidence of immune #exhaustion after repeated #SARS-CoV-2 #vaccination in vulnerable and healthy populations

By G.M.
Abstract Frequent SARS-CoV-2 vaccination in vulnerable populations has raised concerns that this may contribute to T cell exhaustion , which could negatively affect the quality of immune protection. Herein, we examined the impact of repeated SARS-CoV-2 vaccination on T cell phenotypic and functional exhaustion in frail older adults in long-term care (n = 23), individuals on immunosuppressive drugs (n = 10), and healthy adults (n = 43), in Canada . Spike-specific CD4+ and CD8+ T cell levels did not decline in any cohort following repeated SARS-CoV-2 vaccination, nor did the expression of exhaustion markers on spike-specific or total T cells increase. T cell production of multiple cytokines (i.e. polyfunctionality) in response to the spike protein of SARS-CoV-2 did not decline in any cohort following repeated vaccination. None of the cohorts displayed elevated levels of terminally differentiated T cells following multiple SARS-CoV-2 vaccinations. Thus, repeated SARS-CoV-2 vaccination was...
Post a Comment
Read more »

Chimeric #hemagglutinin and #M2 #mRNA #vaccine for broad #influenza subtype protection

By G.M.
Abstract Since multiple and unpredicted influenza viruses cause seasonal epidemics and even high-risk pandemics , developing a universal influenza vaccine is essential to provide broad protection against various influenza subtypes. Combined with the mRNA lipid nanoparticle-encapsulated (mRNA-LNP) vaccine platform and chimeric immunogen strategy , we developed a novel cocktail mRNA vaccine encoding chimeric HAs (cH5/1-BV, cH7/3) and intact M2 (termed Fluaxe), which confers broad protection against major circulating IAVs and IBVs , as well as highly pathogenic avian influenza . Two-dose intramuscular immunization of Fluaxe in mice elicited cross-reactive neutralizing antibodies , T cell responses, and long-lived immunity, resulting in robust protection against multiple lethal influenza virus infections and severe acute lung injuries . In particular, intramuscular administration stimulated systemic immunity together with a prominent lung tropism of memory cells . Moreover, Fluaxe immuniza...
Post a Comment
Read more »